Table I.

Factors predicting lipid-lowering drug therapy among patients with high risk of CVD.

	High risk of CVD
	Medicated n = 942		Non-medicated n = 3881
	%	n	%	n	ORCrude	95 % CI	ORAdjusted	95 % CI
Sex
Male	80	752	90	3491	1		1
Female	20	190	10	390	2.26*	1.87–2.74	1.03	0.78–1.35
Age
< 50	10	98	14	542	1		1
> 50	90	844	86	3339	1.40*	1.11–1.76	1.48*	1.12–1.97
Systolic blood pressure
< 140	32	290	41	1545	1		1
140–160	44	406	43	1641	1.27*	1.08–1.49	1.07	0.89–1.30
160–180	20	181	14	540	1.72*	1.40–2.11	1.05	0.81–1.36
> 180	4	38	2	74	2.63*	1.75–3.97	1.09	0.64–1.85
Total cholesterol
< 6	16	146	37	1422	1		1
6–7	37	346	45	1747	1.78*	1.45–2.17	1.93*	1.55–2.42
7–8	33	4309	16	609	4.55*	3.68–5.63	5.55*	4.31–7.13
> 8	14	126	2	82	13.77*	9.98–19.01	19.84*	13.46–29.22
Smoking status
Non-smoker	50	471	51	1971	1		1
Smoker	50	471	49	1910	1.03	0.89–1.19	0.98	0.83–1.20
Body mass index
< 30	71	670	75	2900	1		1
> 30	29	272	25	981	0.83*	0.71–0.98	0.96	0.79–1.16
IFG and/or IGT
No	81	674	91	3118	1		1
Yes	19	160	9	321	2.31*	1.87–2.84	2.68*	2.11–3.39
Higher education
No	19	175	17	625	1		1
Short	50	452	58	1866	0.90	0.75–1.07	1.09	0.88–1.37
Long	30	273	33	1213	0.83	0.68–1.02	1.03	0.81–1.31
Ethnicity
Danish	90	845	88	3408	1		1
Other	10	97	12	473	1.21	0.96–1.52	1.15	0.88–1.52
Cohabiting
Single	19	181	17	668	1		1
Cohabiting	81	758	83	3186	0.87	0.73–1.05	0.99	0.79–1.24
Polypharmacy
0–1	48	452	70	2724	1		1
2–4	39	366	24	918	2.41*	2.05–2.81	1.35*	1.07–1.71
> 5	13	124	6	239	3.11*	2.45–3.95	1.27	0.88–1.84
Heart/circulation drugs
0	52	489	79	3053	1		1
1	21	197	11	439	2.80*	2.31-3.40	2.41*	2.11-3.47
> 1	27	256	10	389	4.11*	3.42–4.94	4.07*	3.07–5.42
Psychopharmaca
0	85	804	90	3492	1		1
1	7	62	5	190	1.42*	1.05–1.91	1.00	0.70–1.44
> 1	8	76	5	199	1.66*	1.26–2.18	1.06	0.72–1.54
Number of cholesterol measurements
0	39	367	51	1978	1		1
> 0	61	575	49	1903	1.63	1.41–1.88	1.65*	1.39–1.96

Note: *Statistically significant difference between the medicated and the non-medicated group.